Keros receives positive FDA feedback on KER-050 MDS program; Phase 3 design aligned

Keros Therapeutics, Inc.

FDA feedback resulted in general alignment on design and endpoints for proposed pivotal Phase 3 trial of KER-050 (elritercept) in MDS.
Company to host corporate update conference call and webcast on Monday, June 17, 2024 at 8:00 a.m. ET.
Expects to complete enrollment of Phase 2 TROPOS trial evaluating KER-012 (cibotercept) in PAH in Q4 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.